FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

[News]

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

More... (http://www.news-medical.net/news/20131001/FDA-grants-accelerated-approval-to-Perjeta-for-neoadjuvant-treatment-of-breast-cancer.aspx)